1D09C3, an mAb specific for MHC-II.
GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.
Zola
Heddy
H
Women's and Children's Health Research Institute, 72 King William Road, North Adelaide, SA 5006, South Australia. heddy.zola@adelaide.edu.au
Beare
Alice
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity / Q000276:immunology*; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D010330:Patents as Topic; D013329:Structure-Activity Relationship
C528511:1D09C3 monoclonal antibody; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000949:Histocompatibility Antigens Class II